Clinical trials: Rivaroxaban
Spinal Cord Injuries, Thromboembolism
Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
The primary objective of this study is to investigate the pharmacokinetic and -dynamic properties of rivaroxaban after oral administration in cervical spinal cord injury (SCI) individuals.
- Trial name
- rivaroxaban (NCT02970773)
- Testing
- Rivaroxaban Oral Tablet
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Swiss Paraplegic Research, Nottwil
Healthy Subjects
Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
The study was designed as a single-site, randomized, open-label, four-period complete and replicate crossover. A single oral dose of 20 mg rivaroxaban tablet (test) and Xarelto®(reference) was given to the 72 healthy Chinese…
- Trial name
- NCT04424381
- Testing
- Rivaroxaban 20 MG Oral Tablet [Xarelto], Rivaroxaban 20 MG Oral Tablet
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Bariatric Surgery
Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery
The aim of this study is to investigate the efficacy and safety of rivaroxaban in obese patients undergoing bariatric surgery. The objectives are to assess the safety and feasibility of venous thromboembolism (VTE) prophylaxis…
- Trial name
- BARIVA (NCT03522259)
- Testing
- Rivaroxaban 10 MG Oral Tablet [Xarelto]
- Where
- 3 sites in Switzerland
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Venous Thrombosis
Switching Study From Warfarin to Rivaroxaban
The study objective is to investigate the pharmacodynamics (effects of a drug product) when switching the treatment from warfarin to rivaroxaban.
- Trial name
- NCT01507051
- Testing
- Warfarin (Coumadin), Rivaroxaban (Xarelto, BAY59-7939), Vitamin K (Konakion)
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Interaction Study
Rivaroxaban Hypericum Trial
Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy…
- Trial name
- NCT03796377
- Testing
- St Johns Wort Extract, Rivaroxaban
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Bioequivalence
Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions
A single center, open label, randomized, single-dose, two period, Two way cross-over study to explore the Bioequivalence of Test Product Xaroban (Rivaroxaban) 20 mg Tablet with the reference product Xarelto (Rivaroxaban) 20 mg…
- Trial name
- Bioequivalence (NCT04689919)
- Testing
- Rivaroxaban 20 MG Oral Tablet
- Where
- Pakistan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Bariatric Surgery, Morbid Obesity
Pharmacokinetics of Rivaroxaban After Bariatric Surgery
Data on pharmacokinetics of rivaroxaban after bariatric surgery and in morbid obesity are sparse. The aim of this study is to assess the pharmacokinetic and pharmacodynamic parameters of rivaroxaban, used at a therapeutic…
- Trial name
- ABSORB (NCT04180436)
- Testing
- rivaroxaban 20 mg once daily 8 days
- Where
- France
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Healthy
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning.
- Trial name
- RICHAR (NCT02657512)
- Testing
- rivaroxaban, rivaroxaban and activated charcoal
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Healthy Volunteers
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
- Trial name
- DRIVING (NCT01627665)
- Testing
- D->R->C+R, D->R->C+D, R->D->C+D
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
The purpose of this study is to explore the pharmacodynamic (what the drug does to the body) changes when transitioning from rivaroxaban 20 mg once daily to warfarin dosed to a therapeutic level as measured by the International…
- Trial name
- NCT01400646
- Testing
- Rivaroxaban, Warfarin, Vitamin K
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Clinical Pharmacology
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 15 mg in Japanese healthy…
- Trial name
- NCT04511637
- Testing
- Rivaroxaban (BAY 59-7939, Xarelto) in ODT form, Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
- Where
- 3 sites in Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bayer